PDF(Pubmed)
Abstract：
Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.
摘要：
血清监测为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的流行病学以及疫苗引入后人群免疫力的变化提供了背景。这里,我们描述了从2020年2月至2022年7月在纽约市(NYC)进行的基于医院的抗尖峰血清阳性率横断面研究的结果,以及2023年8月至2023年10月的随访期.来自55,092个人的样本，分析了跨越五个流行病学波。使用泊松回归获得患病率比率(PR)。抗尖峰抗体水平在前两波中逐渐增加，在第三波期间急剧增加，与纽约市的SARS-CoV-2疫苗接种相吻合，导致到2022年7月血清阳性率水平>90％。我们的数据提供了对面临新的病毒病原体的大型和多样化大都市社区中免疫动态变化的见解，并反映了大流行过渡到流行阶段时抗体反应的模式。
